

Special Considerations in Insomnia Diagnosis and Management: Depressed, Elderly, and Chronic Pain Populations

Ruth M. Benca, M.D., Ph.D.; Sonia Ancoli-Israel, Ph.D.;
and Harvey Moldofsky, M.D.

Patients with insomnia who also have chronic pain or depression or who are elderly represent segments of the population that are particularly difficult to treat. These populations tend to be at higher risk for experiencing difficulty sleeping and are more likely to experience chronic insomnia, sleep maintenance problems, and/or nonrestorative sleep. Worsening insomnia may exacerbate other somatic and psychological symptoms and vice versa. Conversely, there is evidence that appropriate recognition and management of the sleep complaint may alleviate other symptoms related to the associated condition and help interrupt this vicious cycle. (*J Clin Psychiatry* 2004;65[suppl 8]:26–35)

Insomnia is experienced by many people, with between 20% and 40% of the adult population in the United States experiencing sleep difficulties that range from the transient and occasional to the chronic and severe.^{1–4} However, there are certain populations that are particularly prone to developing sleep difficulties, including individuals with depression, those with chronic pain syndromes, and the elderly. Sleep disturbances in these groups are usually chronic,^{5–8} and, as a result, they are usually more difficult to treat, because currently prescribed hypnotic agents are recommended for short-term use only (i.e., generally 1 month or less).⁹ Adequately addressing sleep disturbance is particularly relevant for these special patients, as there is some evidence that the presence of insomnia is associated with greater severity of a patient's primary condition.^{10–12} This article addresses each of these populations and how their complicating conditions impact the recognition and treatment of insomnia.

From the University of Wisconsin, Madison (Dr. Benca); the University of California, San Diego (Dr. Ancoli-Israel); and the University of Toronto, Toronto, Ontario, Canada (Dr. Moldofsky).

Support was provided through an unrestricted educational grant from Sepracor.

The section "Special Considerations in Insomnia Associated With Depression" was written by Dr. Benca, "Special Considerations in Insomnia in the Elderly" was written by Dr. Ancoli-Israel, and "Special Considerations in Insomnia on Nonrestorative Sleep Associated With Chronic Pain and Fatigue" was written by Dr. Moldofsky.

Corresponding author and reprints: Harvey Moldofsky, M.D., Sleep Disorders Clinic of the Centre for Sleep and Chronobiology, 340 College Street, Suite 580, Toronto, ON M5T 3A9, Canada (e-mail: h.moldofsky@utoronto.ca).

SPECIAL CONSIDERATIONS IN INSOMNIA ASSOCIATED WITH DEPRESSION

Depression is a common illness in the United States, with estimated lifetime prevalence in the general population of about 17%.^{13,14} Sleep disturbance is frequently a symptom of depression and is part of the diagnostic criteria for a major depressive episode (DSM-IV). The association between depression and disturbed sleep has been well documented in both clinical and epidemiologic studies.^{1,15–18}

Linking Insomnia and Depression

Frequent or severe insomnia occurs in 10% to 15% of the adult population^{1,15,19–21} and has been associated with a host of psychological difficulties. A community survey of 3161 adults conducted by Mellinger et al.¹ found that 17% of their sample reported serious insomnia; subjects with any insomnia were more likely to have higher levels of psychic distress, with the highest rate (47%) in the group of serious insomniacs. Several other epidemiologic studies have found that insomnia is associated with a reduced capacity for dealing with stress.^{22,23} Psychological disturbance is not necessarily limited to insomnia with a psychological etiology; Kalogjera-Sackellares and Cartwright²⁴ compared rates of psychopathology between subjects with medically induced insomnias (e.g., related to sleep apnea) and those with psychologically induced insomnias (Diagnostic Classification of Sleep and Arousal Disorders criteria), and found that both groups were equally likely to have elevated scores on the Minnesota Multiphasic Personality Inventory (a measure of psychological functioning, in which higher scores correspond to increasing pathology).


Epidemiologic studies have also found that insomnia is associated with a higher prevalence of psychiatric disorders. Depression or anxiety was reported by 34% of subjects with serious insomnia in the Mellinger et al.¹ community survey, compared with only 12% of subjects without insomnia. Similarly, the National Institute of Mental Health (NIMH) conducted an epidemiologic study in 7954 adults¹⁵ and found that 40% of subjects who reported insomnia over the past 6 months also met criteria for a psychiatric disorder, compared with only 16% of those who did not report insomnia. Breslau et al.¹⁷ determined that the lifetime prevalence of insomnia in young adults (N = 1007) was 25% overall. Among insomniacs, the lifetime prevalence of a psychiatric disorder was 71%, compared with 41% among normal sleepers (odds ratio [OR] = 3.5). The OR for depression with insomnia was 16.6 but was even higher when mixed symptoms of both insomnia and hypersomnia were present (OR = 41.8).¹⁷

A number of studies have found that clinical populations of insomniacs have higher rates of psychiatric comorbidity than do those without insomnia. Over 75% of insomnia patients who were evaluated at a sleep center received a primary or secondary diagnosis of insomnia related to psychiatric disorders (the breakdown of psychiatric diagnoses was not specified) in a multicenter study by Buysse et al.²⁵ In a primary care setting, it is estimated that 50% to 69% of patients with insomnia have a psychiatric disorder.^{3,26,27} Within medical populations, insomnia is more strongly associated with major depression than with other medical disorders.²⁶ Furthermore, women have been found to have higher rates both of insomnia and of anxiety or depression. This observation has been attributed to gender effects on the prevalence of anxiety and depression and not to a gender effect on sleep per se.²⁸

Insomnia Predicts Depression

The NIMH epidemiologic survey found that disturbed sleep was a predictor for developing a psychiatric illness; the odds of developing depression were 39.8 if insomnia was experienced during the preceding year, but those odds were only 1.9 if the insomnia had resolved during that time.¹⁵ Several other studies have found that disturbed sleep is often a harbinger of depression. In a study of 1024 nondepressed men in medical school who were followed for up to 45 years (median = 34 years), insomnia was reported by 137 men, while 887 reported no insomnia.¹⁸ During follow-up, the cumulative incidence of depression was 12.2% (N = 101). Self-reported insomnia and difficulty sleeping under stress were found to be associated with an increased risk for developing depression later in life (Figure 1), as were poor sleep quality and nightly sleep duration of 7 hours or less. After controlling for other potential risk factors for depression, including family history, age, temperament type, and tobacco and alcohol use, self-reported insomnia ($p < .01$) and difficulty sleep-

Figure 1. Cumulative Incidence of Depression in Men With Insomnia (A) and Difficulty Sleeping Under Stress (B)^a



ing under stress ($p < .05$) in young adulthood were still seen to strongly predict the subsequent development of depression.

Several studies have also found that insomnia predicts depression in elderly adults.²⁹⁻³¹ Furthermore, insomnia has been found to be a precursor to the recurrence of depression in patients in clinical remission: the symptoms of sleep disturbance and fatigue preceded the onset of other depressive symptoms including dysphoria, dissatisfaction, crying, and irritability.³² In fact, Breslau et al.¹⁷ found that sleeping difficulty alone has been found to predict depression, even in the absence of other depressive symptoms (OR = 2.1).

Insomnia has also been linked to mania. In a subgroup of patients with bipolar disorder who also had insomnia (77%), insomnia was found to be the most robust early predictor of an impending manic episode.³³ Prodromes

Table 1. Objective Changes in Sleep in Depressed Patients

Reduction in sleep continuity
Decreased total sleep time
Decreased sleep efficiency
Increased sleep latency
Loss of slow-wave sleep
Altered rapid eye movement (REM) patterns
Reduced REM latency
Increased percent time spent in REM
Increased REM activity (eye movements per minute of REM sleep)
REM shifted to earlier in the sleep period

predictive of the onset of a depressive episode in this group of bipolar patients were found to be shorter and more variable in presentation.

Depression Predicts Insomnia

The relationship between insomnia and depression appears to be bidirectional: there is not only evidence suggesting that insomnia may be a predictor of depression, but also that depressed mood may be a predictor of insomnia.³⁴ There is both objective and subjective evidence that sleep is disturbed in depressed patients. Table 1 shows a number of objective changes in sleep that have been observed in patients with depression. In a meta-analysis by Benca and colleagues,¹⁶ sleep changes associated with psychiatric disorders including mood disorder, anxiety, schizophrenia, eating disorder, alcoholism, and insomnia were assessed (Table 2). Patients with mood disorders were found to have more robust changes across more sleep parameters than did patients with other disorders or healthy controls.¹⁶ Polysomnographic recording in depressed patients has also shown the intrusion of alpha activity into delta sleep.³⁵

Subjective assessments of sleep in patients with depression tend to confirm objective measures. Depressed patients have been found to underestimate the amount of sleep they have had, and this phenomenon has been correlated with severity of depression.³⁶ This phenomenon also raises the interesting question of the true nature of improved sleep with treatment of depression: does the insomnia complaint resolve because sleep is actually improved, or does it resolve because the patient's perception of his sleep is improved? Reynolds et al.³⁷ assessed 30 elderly patients with recurrent depression both during an acute episode (baseline) and during symptomatic remission following treatment. Despite improvements in reported sleep, subjective sleep quality during clinical remission in depressed patients still did not reach levels reported by age- and sex-matched healthy controls.³⁷ Objective measures with polysomnographic recording confirmed the subjective reports. Although state markers (e.g., sleep continuity, rapid eye movement [REM] density) improved, sleep did not return to normal. In contrast, trait markers (e.g., shorter REM latency, increased REM volume, loss of slow-wave sleep) persisted even during

Table 2. Sleep in Patients With Psychiatric Disorders Versus Controls^a

Disorder	Sleep Continuity	Slow-Wave Sleep, %	REM Latency	Percent REM
Affective Disorder	↓	↓	↓	↑
Anxiety	↓	•	•	•
Schizophrenia	↓	•	↓	•
Eating disorder	↓	•	↓	•
Alcoholism	↓	↓	•	↑
Insomnia	↓	↓	•	•

^aData from Benca et al.¹⁶

Abbreviation: REM = rapid eye movement. Symbols: ↑ = parameter increased unequivocally relative to controls, ↓ = parameter decreased unequivocally relative to controls, • = no change in parameter relative to controls, ↑ = parameter increased in some studies relative to controls, ↓ = parameter decreased in some studies relative to controls.

depressive remission.³⁷ In clinical experience, this persistence of both subjective and objective sleep disturbance suggests that patients with depression may require long-term insomnia treatment between depressive episodes.

Another possible reason that patients with depression are at a higher risk for insomnia is that many medications used to treat depression may disturb sleep. For example, the selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline, paroxetine, and citalopram, have been found to increase REM latency, suppress REM sleep, cause eye movements during non-REM sleep, and decrease sleep efficiency.³⁸⁻⁴¹ Similarly, venlafaxine (a serotonin and norepinephrine reuptake inhibitor)⁴² and stimulants such as modafinil⁴³ are associated with insomnia. The characteristics of sleep changes caused by these agents include decreased total sleep time and REM sleep, more nighttime arousals, and increased nighttime motor activity.

As well as altering polysomnographic sleep, certain medications can cause other physiologic changes during sleep. Antidepressants have been associated with periodic limb movement disorder.⁴¹ Medications, including the benzodiazepines, have been shown to exacerbate obstructive sleep apnea,^{44,45} and weight gain, which is a side effect of many psychiatric drugs,⁴⁶⁻⁴⁸ also worsens obstructive sleep apnea.

Summary and Future Directions

There is a clear association between depression and insomnia, but a number of important clinical issues remain to be elucidated. One key question is how primary insomnia differs from insomnia associated with a psychiatric disorder and what such differences mean in terms of optimal treatment of insomnia in psychiatric patients. Given that objective and subjective sleep disturbance in patients with depression often extends into periods of clinical remission of the depression, the role of long-term treatment of insomnia for symptomatic relief must be established. Finally, the impact of treating an insomnia complaint on

the likelihood of developing first-onset depression or experiencing depressive relapse is a key question that must be addressed to guide treatment approaches to insomnia in depression.

SPECIAL CONSIDERATIONS IN INSOMNIA IN THE ELDERLY


The number of elderly adults in the United States is rising. The 2000 U.S. census counted 35.0 million people older than 65 years, an increase of 12% since 1990.⁴⁹ Epidemiologic studies among the elderly have estimated that they are disproportionately dissatisfied with their sleep as compared with younger adults.⁵⁰ In the general population, 36% of adults report having sleep difficulties, and 26% are frequent sufferers, experiencing insomnia symptoms for an average of 16 nights or more per month.^{7,21} The National Institute on Aging's Established Populations for Epidemiologic Studies of the Elderly (EPESE) found that 42% of elderly adults frequently had difficulty falling asleep or maintaining sleep or woke up too early in the morning. The consequences of insomnia can be serious in older individuals and can include greater risk of accidents or falling,⁵¹ poorer quality of life,⁵² and higher rates of institutionalization.⁵³ Regardless of an individual's age, disturbed sleep results in a number of adverse outcomes, such as difficulty concentrating, slowed response time (which impacts driving ability), memory impairments, and decreased performance. However, all of these sequelae may be mistaken for dementia in elderly patients in the clinic, adding a layer of complexity to the diagnosis and management of insomnia in these patients.^{54,55}

Given the higher prevalence of sleep loss in elderly populations and its potentially dangerous consequences, it is important to identify and address the special concerns regarding the clinical presentation and management of insomnia in the elderly.

Sleep Disturbances in the Elderly

The incidence of insomnia was estimated in a longitudinal study in which 6899 elderly subjects were assessed for symptoms of sleep disturbance at baseline and again at a 3-year follow-up.³⁴ An annual insomnia incidence rate of roughly 5% was found, with 15% of the 4956 subjects who had no sleep disturbance at baseline reporting symptoms after 3 years. The EPESE interviewed 9282 adults aged 65 years and older and assessed measures of sleep disturbance consisting of trouble falling asleep, awakening during the night, awakening too early, needing to nap during the day, and awakening feeling unrefreshed.⁵⁶ Sleep complaints were more frequent in subjects who had depressed mood, fair to poor health, respiratory symptoms (such as chronic coughing, wheezing, or phlegm), and physical disability, and in those who used medications such as anxiolytics or barbiturates. Those risk factors were

Figure 2. Reported Hours Slept: Older Versus Younger Adults^a



^aData from National Sleep Foundation.⁵⁸ Older adults do not report sleeping fewer hours than younger adults.


also associated with all but 7% of incident cases of insomnia in the longitudinal study,³⁴ as well as with the majority of cases in which insomnia was retained at the 3-year follow-up. Remission of insomnia symptoms was reported by about 50% of subjects who had chronic insomnia at baseline and was associated with improved self-perceived health.³⁴ These findings suggest that insomnia in the elderly is not related to the aging process per se.

As shown in Figure 2, the 2002⁵⁷ and 2003⁵⁸ Sleep in America polls, conducted for the National Sleep Foundation, found that, contrary to common perception, sleep behavior does not differ significantly between older adults (55 to 84 years) and younger adults (18 to 54 years). Specifically, older adults (N = 1506) did not report sleeping fewer hours per night than did younger adults (N = 710), and, in fact, younger adults were the group that reported sleeping the least, with a mean of 6.7 hours per night during the week. Older adults reported sleeping 7.0 hours per night. On weekends, while younger adults' sleeping time increased to 7.6 hours, older adults reported a sleep duration of 7.1 hours, similar to weekday reports.

Sleep problems were correlated with the prevalence in older individuals of medical conditions including heart disease, lung disease, and stroke and with psychiatric illnesses including depression. It was found that subjects with those conditions were more likely to sleep less than 6 hours per night, experience daytime sleepiness, or report at least 1 symptom of insomnia (i.e., difficulty falling asleep, waking a lot during the night, waking up too early and being unable to get back to sleep, and waking up feeling unrefreshed). Once again, these findings suggest that medical illness, rather than aging per se, is associated with sleep disturbance in older adults.

Many medical conditions are known to result in insomnia, and the number of medical diagnoses an individual has tends to increase with age.⁵⁸ Insomnia may be caused by conditions associated with chronic pain, such as ar-

Figure 3. Sleep Problems and Multiple Medical Conditions^a



^aData from National Sleep Foundation.⁵⁸

thritis and cancer; neurologic disorders, such as restless legs syndrome and Alzheimer’s and Parkinson’s diseases; and organ system dysfunctions such as angina, asthma, chronic obstructive pulmonary disease, and gastrointestinal reflux.⁵⁹ The 2003 Sleep in America poll⁵⁸ found that there is a linear relationship between sleep problems and the number of medical diagnoses a subject has (Figure 3), with a greater number of medical conditions conferring a greater likelihood of sleeping less than 6 hours per night, having at least 1 symptom of insomnia, or experiencing daytime sleepiness. Elderly adults who reported having 4 or more medical conditions had higher rates of sleep difficulties than did those with fewer conditions. Twenty-two percent of subjects with 4 or more medical conditions reported sleeping less than 6 hours per night compared with 10% of those with no medical conditions. Similarly, 67% of subjects with 4 or more conditions versus 35% with no conditions reported insomnia, and 27% of subjects with 4 or more conditions versus 5% with no conditions reported daytime sleepiness. Furthermore, multiple medical conditions increased the probability of experiencing unpleasant tingling feelings in the legs or having a diagnosis of a sleep disorder.⁵⁸


Treating Insomnia in the Elderly

Because older individuals frequently have multiple medical conditions, they are also often managed with polypharmacy. A treatment regimen including multiple drugs may increase the risk for insomnia, since many drugs are known to cause sleep disturbance as a side effect (Table 3). The 2003 Sleep in America poll⁵⁸ found that 20% of older adults use sleep-promoting agents, including prescription medications, over-the-counter drugs, and alcohol, a few nights per week or more in order to help them sleep (Figure 4); 15% reported using a sleep aid every night or almost every night. The chronic use of sleep-promoting agents is higher in the elderly than in younger adults; 6% of younger adults reported using a prescription medication and 5% reported using an over-the-counter

Table 3. Drugs That Cause Insomnia

- Alcohol
- Decongestants
- Central nervous system stimulants
- Stimulating antidepressants
- Beta-blockers
- Thyroid hormones
- Bronchodilators
- Nicotine
- Calcium channel blockers
- Caffeine
- Corticosteroids

Figure 4. Use of Substances to Promote Sleep in the Elderly^a



^aData from National Sleep Foundation.⁵⁸ The use of sleep aids is common in the elderly, with prescription medications used most frequently.

agent at least a few times per week, compared with 11% and 6% of older adults who take prescription and over-the-counter medications, respectively. However, due to differing drug metabolism associated with aging, caution should be used in administering pharmacotherapy in the elderly,⁶⁰ and nonpharmaceutical approaches, such as education regarding proper sleep hygiene and other behavioral methods, are recommended as supportive therapies.^{54,60,61}

Summary

In summary, conditions or circumstances that are frequently faced by older adults such as medical illness and polypharmacy can result in insomnia. These data suggest that although insomnia is very common in elderly populations, it does not appear to be intrinsic to the aging process itself.

SPECIAL CONSIDERATIONS IN INSOMNIA ON NONRESTORATIVE SLEEP ASSOCIATED WITH CHRONIC PAIN AND FATIGUE

Chronic pain is associated with a high insomnia prevalence.⁷¹ Pain appears to worsen sleep difficulties, and sleep difficulties appear to worsen the perception of pain.⁸⁷ Patients with pain syndromes experience the gamut of insomnia symptoms, with high rates of sleep maintenance

problems, sleep onset problems, and reports of nonrestorative sleep. Elucidating the link between pain and insomnia can help guide treatment decisions and alleviate patient suffering. This brief review is not intended to be comprehensive and will be limited to a discussion of the pain associated with rheumatologic conditions and its relation to nonrestorative sleep.

Prevalence of Insomnia/Nonrestorative Sleep in Patients With Chronic Pain

DSM-IV describes 3 categories of sleep disturbance in the diagnostic criteria for insomnia⁶²: difficulties in sleep onset (or initiation), difficulties in sleep maintenance, and nonrestorative sleep. The first 2 categories, difficulties in initiating and maintaining sleep, are the more commonly studied and are characterized by disturbances in the quantity of sleep. The third and less commonly studied category, nonrestorative sleep, is qualitative rather than quantitative in nature. Nonrestorative sleep is particularly frequent among individuals with complaints of chronic musculoskeletal pain and with fatigue such as occurs with fibromyalgia or chronic fatigue syndrome (CFS).^{64,76}

Insomnia has been associated with a number of chronic somatic health disorders, including chronic pain. An epidemiologic study of somatic diseases (including hypertension, obstructive pulmonary disease, and rheumatic disease) found that problems with sleep maintenance were as common as problems with initiating sleep (22.4% and 21.2%, respectively).⁸ Fatigue-related disorders such as CFS⁶³ and fibromyalgia^{64,65} have also been associated with disturbed sleep. In fibromyalgia, rates of sleep disorder range from 62% to 95%.⁶⁶⁻⁶⁹ In CFS, the overall rate of sleep disorders in one study was 87% (including inadequate sleep hygiene in 69% of patients, restless legs syndrome in 35%, and sleep disorders associated with mood disorders in 28%),⁶³ and, in another study, 93% of patients experienced disturbed sleep.⁶⁶ Sleep maintenance difficulty was the primary sleep complaint of patients with CFS, regardless of the presence of a psychiatric disorder.⁶³ Tishler et al.⁷⁰ found that, in patients with the autoimmune disorder Sjogren's syndrome, the presence of fibromyalgia (in 36 of 65 patients) was associated with the presence of sleep disturbances (moderate or severe, found in 49 of 65 patients).

Conditions involving chronic pain are especially associated with disturbed sleep. In an analysis of cross-sectional data from the 1991 Canadian General Social Survey, Sutton et al.⁷¹ found that, while subjects with chronic medical illnesses generally had increased likelihood of having insomnia ("trouble going to sleep or staying asleep"), the highest ORs were found with pain-related conditions, compared with conditions that are not as strongly characterized by pain, such as allergy, diabetes, and circulatory disease. For example, 38% of patients with rheumatic diseases experienced insomnia (OR = 2.45;

Table 4. Sleep and Wake Symptoms Associated With Nonrestorative Sleep

Sleep Symptoms
A feeling that sleep is light or superficial
A lack of feeling refreshed upon awakening
Wake Symptoms
Physical and mental fatigue
Variable nonspecific pain
Hypersensitivity to noxious stimuli
Dysphoria
Autonomic disturbances

95% CI = 2.22 to 2.72) compared with 28% of patients with allergy (OR = 1.35; 95% CI = 1.23 to 1.49). Other studies have described a similar relationship between disturbed sleep and chronic pain. McCracken and Iverson⁷² found that 88.9% of 287 patients seeking treatment in a pain clinic reported at least 1 sleep disturbance, and in patients with arthritis, there is a high prevalence (estimates approaching 60%) of restless sleep.⁷³⁻⁷⁵

Sutton et al.⁷¹ found that insomnia was more likely to be experienced in the presence of pain in general; 44% of respondents who had pain reported insomnia, while only 19% of those with no pain reported insomnia. Increasing pain severity was associated with increasing risk for insomnia: Insomnia was reported by 19% of respondents reporting mild pain (OR = 2.28), by 42% of those reporting moderate pain (OR = 2.99), and by 58% of those reporting severe pain (OR = 5.73). There was a similar relationship between pain and the experience of nonrestorative sleep, which was reported by 34% of respondents with mild pain (OR = 1.58), by 43% of those with moderate pain (OR = 2.39), and by 51% of those with severe pain (OR = 3.35).⁷¹


Nonrestorative sleep has a high prevalence—the 1991 Canadian General Social Survey found that 24% of respondents reported that their sleep is refreshing only sometimes, and 3% reported that their sleep is never refreshing—and is associated with characteristic sleep and waking symptoms⁷⁶ (Table 4). Although there are a number of conditions that are associated with nonrestorative sleep, much of the work investigating the relationship between pain and this type of sleep disturbance has been conducted in fibromyalgia; thus, the discussion here will focus primarily on patients with fibromyalgia.

Nonrestorative Sleep in Fibromyalgia


Nonrestorative sleep is one of the symptoms noted by the American College of Rheumatology in its 1990 criteria for fibromyalgia,⁶⁵ and there is a high prevalence of sleep disorders in both patients with fibromyalgia and patients with CFS. In fact, the behavioral symptoms that characterize fibromyalgia are similar to those that are described earlier in this review and listed in Table 4 characterizing nonrestorative sleep: sleep symptoms of light or superficial sleep or nonrestorative sleep and wake

Figure 5. Three Distinct Electroencephalographic (EEG) Patterns of Alpha Activity During Sleep^a


A. Low Alpha EEG Sleep Pattern^b



B. Phasic Alpha EEG Sleep Pattern^c



C. Tonic Alpha EEG Sleep Pattern^d



^aReprinted with permission from Roizenblatt et al.⁷⁷ The upper plot in each panel (sleep stages) is a hypnogram. The middle plot shows alpha activity during sleep, and the lower plot shows delta activity during sleep.

^bThis pattern is typical of the majority of healthy individuals.

^cThis pattern is characterized by an episodic alpha rhythm occurring concurrently with delta activity. It is a pattern observed in patients with fibromyalgia and is rare in healthy individuals.


^dThis pattern is characterized by the unremitting presence of alpha activity during non-REM sleep that is independent of delta activity. It is more common in patients with fibromyalgia than in healthy individuals.

symptoms of physical and mental fatigue; variable, non-specific pain; autonomic disturbances; and psychological disturbances.⁶⁵

Objective electroencephalogram (EEG) abnormalities that are associated with nonrestorative sleep have been observed in the sleep of patients with fibromyalgia.⁷⁷⁻⁸⁰ Normal, refreshing sleep is characterized by low alpha EEG during slow-wave sleep⁷⁷ (Figure 5A). However, patients with fibromyalgia and nonrestorative sleep have increased alpha activity during non-REM sleep,⁷⁷⁻⁷⁹ an increased alpha/delta power ratio,^{78,80,81} and increased alpha and theta/delta time during slow-wave sleep (in children with fibromyalgia and their mothers).⁸² This nonrestorative sleep in patients with fibromyalgia may exhibit tonic or phasic alpha patterns during slow-wave (alpha/delta) sleep⁷⁷ (Figures 5B and 5C), and may also exhibit periodic EEG sleep disturbances (such as frequent cyclic alternating patterns, including K-alpha or periodic polyphasic patterns, or disturbances accompanying periodic limb movements and periodic sleep apnea or hypopnea).^{77,83} These phasic and tonic increases in EEG alpha activity during non-REM sleep occur in 80% to 90% of patients with fibromyalgia and CFS.^{77,78} Frequent cyclic alternating patterns, periodic K-alpha, or polyphasic EEG bursts occur in 55% of patients; periodic limb movement syndrome occurs in 21%; and sleep apnea occurs in 3%. Furthermore, subjective muscular pain, increased tenderness, and fatigue were shown to be linked to poor sleep in early studies by Moldofsky et al.,^{64,76} in which normal subjects had disruption of stage 4 sleep via auditory stimulation at the onset of slow-wave (deep) sleep. The emergence of pain and fatigue symptoms in healthy sleepers was repeated in subsequent experimental studies of disruption of slow-wave sleep with nonspecific auditory arousals.^{84,85}

Wolfe et al.⁸⁶ characterized the clinical features and predictors associated with fatigue in 1488 patients with rheumatic disease, including rheumatoid arthritis, osteoarthritis, and fibromyalgia. They found that fatigue was reported by 88% to 98% of patients. Fatigue occurred in 41% of patients with rheumatoid arthritis or osteoarthritis and in 76% of those with fibromyalgia. Sleep disorder, depression, and pain were among the strongest independent predictors of fatigue, with these features accounting for roughly 90% of the variance of fatigue (R^2 for all patients = 0.51, rheumatoid arthritis = 0.49, osteoarthritis = 0.45, fibromyalgia = 0.41). Affleck et al.⁸⁷ conducted a 30-day study of fibromyalgia subjects and showed that poorer sleepers report more pain: The poorer sleep is on a given night, the more pain will be experienced the following day. Conversely, the more pain experienced during the day, the poorer that night's sleep will be. Similarly, Nicassio et al.⁸⁸ showed that a dysfunctional cyclical pattern of heightened pain and nonrestful sleep underlies the experience of fatigue in fibromyalgia patients; thus, poor sleep quality can be seen to mediate pain and fatigue.

Figure 6. Mean Multiple Sleep Latency Test (MSLT) Scores After 6 Nights of Treatment With Triazolam in Patients With Rheumatoid Arthritis^a



^aReprinted with permission from Walsh et al.⁹⁵ Mean latencies of onset to sleep on the MSLT were longer with triazolam than with placebo. Differences were significant at 1400, 1600, and 1800 hours.

Management

Appropriate treatment of the symptoms of sleep disturbance is an important component to managing patients with chronic pain or fatigue. Clinical assessment of sleep disorders should include an interview of both the chronic pain patient and a family member to ascertain sleep habits and symptoms that include the quantity and quality of sleep, number of awakenings, presence of snoring, and restlessness or movement of limbs, as well as daytime waking behavior such as energy, alertness, cognitive functions, and mood.^{89,90} Behavioral assessments can be made using scales⁹¹ such as the Sleep Assessment Questionnaire, which includes 6 sleep factors: insomnia/hypersomnia, nonrestorative sleep, sleep-schedule disorder, excessive daytime somnolence, sleep apnea, and restlessness.

To objectively clarify the complaint of nonrestorative sleep—especially for determining tonic or periodic EEG sleep disturbances (i.e., frequent cyclic alternating patterns, sleep apnea, periodic movements in sleep) or if the diagnosis is unclear—the patient may be referred to a comprehensive sleep clinic for polysomnography and clinical assessment by a sleep medicine specialist.^{89,90} The Multiple Sleep Latency Test (MSLT) is useful for differentiating daytime sleepiness from physical and mental fatigue.⁹⁰

A number of nonspecific treatments can be used in managing nonrestorative sleep. Behavioral methods that may be useful in fibromyalgia and CFS include cognitive-behavioral psychotherapy,^{90,92,93} sleep hygiene,^{90,92} and a suitable aerobic fitness program.⁹⁰ These methods may also be beneficial in the treatment of rheumatoid arthritis and other chronic pain conditions.^{93,94} Among pharmacologic treatments, triazolam has been shown, in a double-blind, placebo-controlled crossover study in patients with

rheumatoid arthritis, to improve measures of sleep, daytime sleepiness, and morning stiffness.⁹⁵ Mean latencies to onset of EEG sleep, as measured by the MSLT, were longer after treatment with triazolam than with placebo (Figure 6). While tricyclic agents such as amitriptyline^{96–98} improve sleep, they do not reduce the EEG abnormalities associated with sleep-arousal disorders such as alpha activity during non-REM sleep.⁹⁹ Similarly, the nonbenzodiazepine hypnotics zolpidem¹⁰⁰ and zopiclone,¹⁰¹ and investigational agents such as 5-hydroxy-L-tryptophan¹⁰² and growth hormone,¹⁰³ may improve sleep quality, but their impact on EEG sleep disturbances is uncertain. Sodium oxybate, a form of gamma hydroxybutyrate, is reported in one randomized, double-blind, placebo-controlled study to improve pain, fatigue, and non-restorative sleep by reducing the EEG alpha activity and increasing slow-wave sleep in patients with fibromyalgia.¹⁰⁴ Large-scale studies are required to verify these important findings.

Summary

Pain (such as that associated with rheumatologic conditions) and nonrestorative sleep appear to mutually exacerbate one another, such that sleep disturbance worsens a patient's pain, and pain worsens a patient's sleep disturbance. In patients with fibromyalgia, there is evidence that this bidirectional link between nonrestorative sleep and chronic musculoskeletal pain and fatigue may be mediated by characteristic EEG abnormalities such as the alpha EEG sleep disorder and periodic EEG sleep disturbances (i.e., frequent cyclic alternating pattern, sleep apnea, and periodic limb movements). While symptomatic control of acute pain helps to alleviate insomnia, the chronic musculoskeletal pain and fatigue may in turn be successfully managed with treatment of coincident poor-quality sleep.

CONCLUSIONS

The diagnosis and treatment of insomnia, which is always challenging, is more complicated in individuals with medical or psychiatric illness and in the elderly. Not only do these populations have higher rates of insomnia than do healthy, younger adults, but they are also more likely to have persistent and difficult-to-treat symptoms, such as sleep-maintenance problems. Although treating primary conditions such as depression, chronic pain, or illnesses associated with aging may help alleviate insomnia symptoms indirectly, adequate pharmacologic and behavioral therapy targeted to the sleep disturbances themselves are important in these patients. To that end, gaining a better understanding of the underlying pathophysiology associated with insomnia and identifying the associated risk factors will help improve diagnosis, allow for better treatment decisions, and aid in the development of new therapies.

Drug names: amitriptyline (Elavil and others), citalopram (Celexa), fluoxetine (Prozac and others), modafinil (Provigil), paroxetine (Paxil and others), sertraline (Zoloft), sodium oxybate (Xyrem), triazolam (Halcion and others), venlafaxine (Effexor), zolpidem (Ambien).

REFERENCES

- Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment: prevalence and correlates. *Arch Gen Psychiatry* 1985;42:225–232
- Bixler EO, Kales A, Soldatos CR, et al. Prevalence of sleep disorders in the Los Angeles metropolitan area. *Am J Psychiatry* 1979;136:1257–1262
- Charon F, Dramaix M, Mendlewicz J. Epidemiological survey of insomniac subjects in a sample of 1,761 outpatients. *Neuropsychobiology* 1989;21:109–110
- Roth T. Introduction: new developments for treating sleep disorders. *J Clin Psychiatry* 2001;62(suppl 10):3–4
- McCall WV. A psychiatric perspective on insomnia. *J Clin Psychiatry* 2001;62(suppl 10):27–32
- Asplund R. Sleep disorders in the elderly. *Drugs Aging* 1999;14:91–103
- Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey, 1. *Sleep* 1999;22(suppl 2):S347–S353
- Gislason T, Almqvist M. Somatic diseases and sleep complaints: an epidemiological study of 3,201 Swedish men. *Acta Med Scand* 1987;221:475–481
- Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2003
- Richardson GS, Roth T. Future directions in the management of insomnia. *J Clin Psychiatry* 2001;62(suppl 10):39–45
- Thase ME, Simons AD, Reynolds CF III. Abnormal electroencephalographic sleep profiles in major depression: association with response to cognitive behavior therapy. *Arch Gen Psychiatry* 1996;53:99–108
- Agargun MY, Kara H, Solmaz M. Sleep disturbances and suicidal behavior in patients with major depression. *J Clin Psychiatry* 1997;58:249–251
- Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. *Arch Gen Psychiatry* 1994;51:8–19
- Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA* 2003;289:3095–3105
- Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? *JAMA* 1989;262:1479–1484
- Benca RM, Obermeyer WH, Thisted RA, et al. Sleep and psychiatric disorders: a meta-analysis. *Arch Gen Psychiatry* 1992;49:651–668
- Breslau N, Roth T, Rosenthal L, et al. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. *Biol Psychiatry* 1996;39:411–418
- Chang PP, Ford DE, Mead LA, et al. Insomnia in young men and subsequent depression: the Johns Hopkins Precursors Study. *Am J Epidemiol* 1997;146:105–114
- Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. *Am J Psychiatry* 1997;154:1417–1423
- National Sleep Foundation. Sleep in America: a national survey of US adults. Princeton, NJ: The Gallup Organizations; 1991
- National Sleep Foundation. Sleep in America: 1995 Gallup Poll. Available at: <http://www.sleepfoundation.org/publications/SleepInAmerica1995.cfm>. Accessed March 2, 2004
- Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey, 2. *Sleep* 1999;22(suppl 2):S354–S358
- Kim K, Uchiyama M, Okawa M, et al. An epidemiological study of insomnia among the Japanese general population. *Sleep* 2000;23:41–47
- Kalogjera-Sackellares D, Cartwright RD. Comparison of MMPI profiles in medically and psychologically based insomnias. *Psychiatry Res* 1997;70:49–56
- Buysse DJ, Reynolds CF III, Kupfer DJ, et al. Clinical diagnoses in 216 insomnia patients using the International Classification of Sleep Disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV Field Trial. *Sleep* 1994;17:630–637
- Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. *Arch Intern Med* 1998;158:1099–1107
- Shochat T, Umphress J, Israel AG, et al. Insomnia in primary care patients. *Sleep* 1999;22(suppl 2):S359–S365
- Voderholzer U, Al Shajlawi A, Weske G, et al. Are there gender differences in objective and subjective sleep measures? a study of insomniacs and healthy controls. *Depress Anxiety* 2003;17:162–172
- Dryman A, Eaton WW. Affective symptoms associated with the onset of major depression in the community: findings from the US National Institute of Mental Health Epidemiologic Catchment Area Program. *Acta Psychiatr Scand* 1991;84:1–5
- Livingston G, Blizard B, Mann A. Does sleep disturbance predict depression in elderly people? a study in inner London. *Br J Gen Pract* 1993;43:445–448
- Cole MG, Dendukuri N. Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. *Am J Psychiatry* 2003;160:1147–1156
- Perlis ML, Giles DE, Buysse DJ, et al. Which depressive symptoms are related to which sleep electroencephalographic variables? *Biol Psychiatry* 1997;42:904–913
- Jackson A, Cavanagh J, Scott J. A systematic review of manic and depressive prodromes. *J Affect Disord* 2003;74:209–217
- Foley DJ, Monjan A, Simonsick EM, et al. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. *Sleep* 1999;22(suppl 2):S366–S372
- Hauri P, Hawkins DR. Alpha-delta sleep. *Electroencephalogr Clin Neurophysiol* 1973;34:233–237
- Tsuyuhama K, Nagayama H, Kudo K, et al. Discrepancy between subjective and objective sleep in patients with depression. *Psychiatry Clin Neurosci* 2003;57:259–264
- Reynolds CF III, Hoch CC, Buysse DJ, et al. Sleep in late-life recurrent depression: changes during early continuation therapy with nortriptyline. *Neuropsychopharmacology* 1991;5:85–96
- Lustberg L, Reynolds CF. Depression and insomnia: questions of cause and effect. *Sleep Med Rev* 2000;4:253–262
- Rush AJ, Armitage R, Gillin JC, et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. *Biol Psychiatry* 1998;44:3–14
- Trivedi MH, Rush AJ, Armitage R, et al. Effects of fluoxetine on the polysomnogram in outpatients with major depression. *Neuropsychopharmacology* 1999;20:447–459
- Dorsey CM, Lukas SE, Cunningham SL. Fluoxetine-induced sleep disturbance in depressed patients. *Neuropsychopharmacology* 1996;14:437–442
- Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. *J Clin Psychiatry* 1998;59:116–122
- Provigil (modafinil). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002:1193–1196
- Ancoli-Israel S, Kripke DF, Zorick F, et al. Effects of a single dose of flurazepam on the sleep of healthy volunteers. *Arzneimittelforschung* 1984;34:99–100
- Berry RB, Kouchi K, Bower J, et al. Triazolam in patients with obstructive sleep apnea. *Am J Respir Crit Care Med* 1995;151(2, pt 1):450–454
- Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. *Am J Psychiatry* 1999;156:1686–1696
- Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. *Acta Psychiatr Scand* 2000;101:416–432
- Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. *Drug Saf* 2001;24:969–978
- Hertzel L, Smith A. Census 2000 Brief: the 65 years and over population: 2000. Available at: <http://www.census.gov/prod/2001pubs/c2kbr01-10.pdf>. Accessed Sept 10, 2002
- Vitiello MV. Sleep disorders and aging: understanding the causes. *J Gerontol A Biol Sci Med Sci* 1997;52:M189–M191
- Brassington GS, King AC, Bliwise DL. Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64–99 years. *J Am Geriatr Soc* 2000;48:1234–1240
- Schubert CR, Cruickshanks KJ, Dalton DS, et al. Prevalence of sleep problems and quality of life in an older population. *Sleep* 2002;25:889–893

53. Pollak CP, Perlick D, Linsner JP, et al. Sleep problems in the community elderly as predictors of death and nursing home placement. *J Community Health* 1990;15:123–135
54. Ancoli-Israel S. Insomnia in the elderly: a review for the primary care practitioner. *Sleep* 2000;23(suppl 1):S23–S30
55. National Heart Lung and Blood Institute. *Insomnia: Assessment and Management in Primary Care*. National Institutes of Health: Bethesda, Md; 1998. NIH publication 98-4088
56. Foley DJ, Monjan AA, Brown SL, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. *Sleep* 1995;18:425–432
57. National Sleep Foundation. 2002 Sleep in America Poll. Washington, DC: WB & A Market Research; 2002:1–43
58. National Sleep Foundation. 2003 Sleep in America Poll. Washington, DC: WB & A Market Research; 2003:1–46
59. Shochat T, Loredo J, Ancoli-Israel S. Sleep disorders in the elderly. *Curr Treat Options Neurol* 2001;3:19–36
60. Reynolds CF III, Regestein Q, Nowell PD, et al. Treatment of insomnia in the elderly. In: Salzman C, ed. *Clinical Geriatric Psychopharmacology*. 3rd ed. Baltimore, MD: Williams & Wilkins; 1998:395–416
61. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. *JAMA* 1999;281:991–999
62. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision*. Washington, DC: American Psychiatric Association; 2000
63. Morriss RK, Wearden AJ, Battersby L. The relation of sleep difficulties to fatigue, mood and disability in chronic fatigue syndrome. *J Psychosom Res* 1997;42:597–605
64. Moldofsky H, Scarisbrick P, England R, et al. Musculoskeletal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. *Psychosom Med* 1975;37:341–351
65. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: Report of the Multicenter Criteria Committee. *Arthritis Rheum* 1990;33:160–172
66. Goldenberg DL. Fibromyalgia and its relation to chronic fatigue syndrome, viral illness and immune abnormalities. *J Rheumatol Suppl* 1989;19:91–93
67. Yunus MB, Masi AT, Aldag JC. A controlled study of primary fibromyalgia syndrome: clinical features and association with other functional syndromes. *J Rheumatol Suppl* 1989;19:62–71
68. Triadafilopoulos G, Simms RW, Goldenberg DL. Bowel dysfunction in fibromyalgia syndrome. *Dig Dis Sci* 1991;36:59–64
69. Sivri A, Cindas A, Dincer F, et al. Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients. *Clin Rheumatol* 1996;15:283–286
70. Tishler M, Barak Y, Paran D, et al. Sleep disturbances, fibromyalgia and primary Sjogren’s syndrome. *Clin Exp Rheumatol* 1997;15:71–74
71. Sutton DA, Moldofsky H, Badley EM. Insomnia and health problems in Canadians. *Sleep* 2001;24:665–670
72. McCracken LM, Iverson GL. Disrupted sleep patterns and daily functioning in patients with chronic pain. *Pain Res Manag* 2002;7:75–79
73. Nicassio PM, Wallston KA. Longitudinal relationships among pain, sleep problems, and depression in rheumatoid arthritis. *J Abnorm Psychol* 1992;101:514–520
74. Drewes AM, Jennum P, Andreassen A, et al. Self-reported sleep disturbances and daytime complaints in women with fibromyalgia and rheumatoid arthritis. *J Musculoskeletal Pain* 1994;2:15–31
75. Moffitt PF, Kalucy EC, Kalucy RS, et al. Sleep difficulties, pain and other correlates. *J Intern Med* 1991;230:245–249
76. Moldofsky H, Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. *Psychosom Med* 1976;38:35–44
77. Roizenblatt S, Moldofsky H, Benedito-Silva AA, et al. Alpha sleep characteristics in fibromyalgia. *Arthritis Rheum* 2001;44:222–230
78. Branco J, Atalaia A, Paiva T. Sleep cycles and alpha-delta sleep in fibromyalgia syndrome. *J Rheumatol* 1994;21:1113–1117
79. Drewes AM, Gade K, Nielsen KD, et al. Clustering of sleep electroencephalographic patterns in patients with the fibromyalgia syndrome. *Br J Rheumatol* 1995;34:1151–1156
80. Nielsen KD, Drewes AM, Svendsen L, et al. Ambulatory recording and power spectral analysis by autoregressive modelling of polygraphic sleep signals in patients suffering from chronic pain. *Methods Inf Med* 1994;33:76–78
81. Drewes AM, Nielsen KD, Taagholt SJ, et al. Sleep intensity in fibromyalgia: focus on the microstructure of the sleep process. *Br J Rheumatol* 1995;34:629–635
82. Roizenblatt S, Tufik S, Goldenberg J, et al. Juvenile fibromyalgia: clinical and polysomnographic aspects. *J Rheumatol* 1997;24:579–585
83. MacFarlane JG, Shahal B, Mously C, et al. Periodic K-alpha sleep EEG activity and periodic limb movements during sleep: comparisons of clinical features and sleep parameters. *Sleep* 1996;19:200–204
84. Lentz MJ, Landis CA, Rothermel J, et al. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. *J Rheumatol* 1999;26:1586–1592
85. Older SA, Battafarano DF, Danning CL, et al. The effects of delta wave sleep interruption on pain thresholds and fibromyalgia-like symptoms in healthy subjects: correlations with insulin-like growth factor I. *J Rheumatol* 1998;25:1180–1186
86. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. *J Rheumatol* 1996;23:1407–1417
87. Affleck G, Urrows S, Tennen H, et al. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. *Pain* 1996;68:363–368
88. Nicassio PM, Moxham EG, Schuman CE, et al. The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. *Pain* 2002;100:271–279
89. Moldofsky H. The contribution of sleep medicine to the assessment of the tired patient. *Can J Psychiatry* 2000;45:798–802
90. Moldofsky H. Management of sleep disorders in fibromyalgia. *Rheum Dis Clin North Am* 2002;28:353–365
91. Reeves WC, Nisenbaum R, Moldofsky H, et al. Sleep assessment in a population-based study of chronic fatigue syndrome [abstract]. *Sleep* 2003;26:A370
92. Currie SR, Wilson KG, Pontefract AJ, et al. Cognitive-behavioral treatment of insomnia secondary to chronic pain. *J Consult Clin Psychol* 2000;68:407–416
93. Keefe FJ, Caldwell DS. Cognitive behavioral control of arthritis pain. *Med Clin North Am* 1997;81:277–290
94. Davis GC. Improved sleep may reduce arthritis pain. *Holist Nurs Pract* 2003;17:128–135
95. Walsh JK, Muehlbach MJ, Lauter SA, et al. Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis. *J Rheumatol* 1996;23:245–252
96. Crette S, McCain GA, Bell DA, et al. Evaluation of amitriptyline in primary fibrositis: a double-blind, placebo-controlled study. *Arthritis Rheum* 1986;29:655–659
97. Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. *Arthritis Rheum* 1996;39:1852–1859
98. Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. *Br J Rheumatol* 1998;37:1279–1286
99. Crette S, Oakson G, Guimont C, et al. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. *Arthritis Rheum* 1995;38:1211–1217
100. Moldofsky H, Lue FA, Mously C, et al. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. *J Rheumatol* 1996;23:529–533
101. Drewes AM, Andreassen A, Jennum P, et al. Zopiclone in the treatment of sleep abnormalities in fibromyalgia. *Scand J Rheumatol* 1991;20:288–293
102. Puttini PS, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. *J Int Med Res* 1992;20:182–189
103. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. *Am J Med* 1998;104:227–231
104. Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. *J Rheumatol* 2003;30:1070–1074